FOR IMMEDIATE RELEASE

Contact: Ronald Trahan, APR,
Ronald Trahan Associates Inc., +1508-816-6730

Tricuspid Valve Repair Company 4Tech Inc. Appoints
Tom Fleming as President and CEO, and Dr. Keith Dawkins as CMO

GALWAY, Ireland, Feb. 22, 2018 — 4Tech Inc., a leader in the field of transcatheter tricuspid valve repair, announces changes in its leadership team: Tom Fleming will join the company as President and Chief Executive Officer (CEO), effective as of March 2018; and Keith D. Dawkins, M.D., has joined as Chief Medical Officer (CMO), effective immediately. Tom Fleming replaces Mike Ennen, who is stepping down for family reasons. This new leadership team enhances the company’s strategy to advance its clinical program for TriCinch™ Coil System.

Tom Fleming comes to 4Tech with over 21 years of experience at Boston Scientific Corporation in numerous roles of increasing responsibility, including Vice President (VP) and General Manager (GM) for Transcatheter Aortic Valves, Program Management, Interventional Cardiology, Cardiac Rhythm Management and Peripheral Interventions. He also held leadership roles in Imaging, Embolic Protection, Quality, and Marketing. In his most recent role as Vice President and General Manager for the Transcatheter Aortic Valve (TAVR), 2012 - 2017, he was responsible for leading Boston Scientific into the $3B global market for minimally invasive Transcatheter Aortic Valves. With the Clinical Investigators and Boston Scientific team, he successfully drove the execution of the first comparative head-to-head randomized US IDE trial, which demonstrated superiority at one year.

Keith D. Dawkins, M.D. served as the Executive Vice President and Global Chief Medical Officer at Boston Scientific for all divisions, 2012 – 2017, where he was responsible for enhancing the company’s global clinical programs and strategies. Previously, he served as Senior Vice President and CMO for Boston Scientific’s Cardiology Rhythm and Vascular Group. Prior to joining Boston Scientific, Dr. Dawkins was a practicing interventional cardiologist for over 20 years in England. He has earned a series of clinical, research and academic distinctions, including a post-doctoral research fellowship at Stanford University as a Fulbright Scholar. Dr. Dawkins also served as President of the British Cardiovascular Intervention Society and held numerous appointments on hospital, regional and national committees, including the National Institute for Health and Clinical Excellence (NICE). He has been an author on more than 750 academic publications and presentations on a variety of cardiac topics.

“The board and I are delighted to welcome Tom and Keith to the organization. Given both of their track records, strong leadership skills and tremendous experience and knowledge in medical devices, they will be strong contributors in advancing our program and driving success for 4Tech and the TriCinch Coil System,” said Bill Hawkins, Chairman of the Board of Directors. “We would also like to thank Mike Ennen for his contributions to the company and wish him the best with his future endeavors.”
“This is an exciting time for 4Tech and I am thrilled to be joining the team as president and CEO,” said Tom Fleming. “The team has made innovative advancements with the TriCinch Coil System, which I am confident will be a meaningful addition to the Structural Heart toolbox. I am excited to build upon the foundation that has been put in place and further accelerate our efforts to provide an alternative solution for patients suffering from tricuspid regurgitation.”

“I am excited to have the opportunity to join 4Tech as CMO,” said Keith Dawkins. “I look forward to working with the team on building a robust clinical program that will support the TriCinch Coil System, which I believe is a promising percutaneous solution for treating tricuspid valve disease.”

About Tricuspid Regurgitation (TR)
Tricuspid regurgitation is a difficult-to-manage, age-related disease in which blood “backflows” into the right side of the heart. Today’s standard of care for TR is medical management. Surgical intervention is very high-risk. In-hospital death post-cardiac surgery for isolated TR can be as high as 37%1. Unfortunately, patients with TR tend to be non-compliant with their medications. Thus, TR and related complications induce substantial healthcare spending due to frequent re-hospitalizations. Furthermore, TR leads to chronic renal failure and the need for end-stage dialysis. The combination of these negative outcomes results in a significant unmet need for an interventional cardiology solution to TR.

About 4Tech Inc.
4Tech Inc. (www.4techtricuspid.com) is incorporated in Delaware, USA, with operations in Galway, Ireland (4Tech Cardio Ltd). 4Tech has developed a proprietary transcatheter solution for the treatment of TR. Because of its unique anchoring and tensioning mechanism, the 4Tech TriCinch™ Coil System for Transcatheter Tricuspid Valve Repair (TTVR) potentially allows a simple and reproducible percutaneous procedure, designed to reduce TR and restore patient quality of life.

Caution: The 4Tech TriCinch™ Coil System for Transcatheter Tricuspid Valve Repair is in the early clinical phase of development. It will not be available in the USA for clinical trials until further notice and is NOT available for sale.

Caution: This news release contains certain “forward-looking” statements under the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of 4Tech are based on management’s current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. Factors that could cause or contribute to such differences may include, but are not limited to, risks relating to the protection of intellectual property, changes to governmental regulation of medical devices, the FDA’s approval of new products, the impact of competitive products, changes to the competitive environment, the acceptance of new products in the market, conditions of the interventional cardiology industry and the economy and other factors.